Source-grounded facts extracted from biote Corp.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Robert Peterson was appointed as Interim Chief Executive Officer at biote Corp..
“On June 12, 2026, in connection with his appointment as Interim Chief Executive Officer, Mr. Peterson and BioTE entered into an amended and restated employment agreement”
Marc Beer was appointed as Executive Chairman of the Board at biote Corp..
“On June 1, 2026, the Board appointed Marc Beer as Executive Chairman of the Board, effective June 8, 2026.”
Robert Peterson was appointed as Interim Chief Executive Officer at biote Corp..
“Concurrently, the Board appointed Robert Peterson, current Chief Financial Officer and Chief Business Officer of BioTE, as Interim Chief Executive Officer of BioTE to fill the vacancy created by Mr. Christensen’s resignation, and as a director of the Board, each effective June 8, 2026 (the “Effective Date”).”
Bret Christensen resigned as Chief Executive Officer at biote Corp..
“On May 27, 2026, the Board of Directors (the “Board”) of biote Corp. (the “Company”) accepted the resignation of Bret Christensen, the Company’s Chief Executive Officer, from his position as Chief Executive Officer of BioTE Medical, LLC (“BioTE”), effective as of June 8, 2026.”
biote Corp. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-12 meeting.
“Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
biote Corp. shareholders approved Election of Class I directors at the 2026-05-12 meeting.
“Proposal 1: Election of Directors The Company’s stockholders elected the two individuals listed below to serve as Class I directors until the Company’s 2029 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal.”
biote Corp. reported the first quarter ended March 31, 2026 results: revenue Revenue of $44.9 million, net income Net income of $2.7 million, EPS diluted earnings per share attributable to biote Corp. stockholders of $0.06.
“Results Sales team expansion on track and nearing targeted level Return to procedure growth expected in second half of 2026 First Quarter 2026 Financial Highlights • Revenue of $44.9 million • Gross profit margin of 68.9% • Net income of $2.7 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $15.8”
biote Corp. reported Full Year 2025 results: revenue $192.2 million, net income $31.6 million, EPS $0.74 per diluted share.
“Full Year 2025 Financial Highlights • Revenue of $192.2 million • Gross profit margin of 71.5% • Net income of $31.6 million and diluted earnings per share attributable to biote Corp. stockholders of $0.74 per diluted share, compared to net income of $0.05 million and diluted earnings per share attributable to biote Corp. stockholders of $0.09 in 2024”
biote Corp. reported the fourth quarter and fiscal year ended December 31, 2025 results: revenue $46.4 million, net income $2.6 million, EPS $0.06.
“expansion to capture large growth opportunity Anticipate a return to procedure revenue growth in the second half of 2026 Fourth Quarter 2025 Financial Highlights • Revenue of $46.4 million • Gross profit margin of 68.0% • Net income of $2.6 million and diluted earnings per share attributable to biote Corp. stockholders of $0.06, compared to net income of $3.5”
Steven J. Heyer resigned as Director at biote Corp..
“vacancy created by the prior resignation of Steven J. Heyer”
Richard R. Barrera was appointed as Director at biote Corp..
“On June 5, 2025, the Board of Directors (the “Board”) of biote Corp. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee, appointed Richard R. Barrera to serve as a member of the Board to fill the vacancy created by the prior resignation of Steven J. Heyer”
Steven J. Heyer resigned as member of the Board at biote Corp..
“On June 2, 2025, Steven J. Heyer notified the Board of Directors (the “Board”) of biote Corp. (the “Company”) of his resignation as a member of the Board, effective immediately.”
biote Corp. announced a restructuring with charges of approximately $0.6 to $0.8 million affecting commercial teams (16 employees).
“maximize value from existing top-tier providers and strengthen accountability and discipline throughout the organization. The Company estimates that it will incur approximately $0.6 to $0.8 million in pre-tax restructuring charges, which represent future cash expenditures for the payment of one-time severance benefits and other associated costs. The Company”
Marc Beer changed role as Executive Chairman at biote Corp..
“On April 1, 2025 (the “Effective Date”), Marc Beer, biote Corp.’s (the “Company”) Executive Chairman, transitioned from full-time employment to part-time employment (the “Transition”), consistent with the Board of Directors’ transition plan of leadership.”
Bret Christensen was appointed as Chief Executive Officer at biote Corp..
“appointed Bret Christensen as Chief Executive Officer (principal executive officer) of the Company and as a member of the Board to fill the vacancy created by Ms. Weber’s resignation, effective as of the Effective Date.”
Teresa S. Weber resigned as Chief Executive Officer at biote Corp..
“accepted the resignation of Teresa S. Weber, the Company’s Chief Executive Officer, from all positions she holds with the Company, including stepping down from the Board, effective as of February 1, 2025”
Mary Puncochar was terminated as Head of Strategic Sales & Business Analytics at biote Corp..
“On July 2, 2024, biote Corp. (the “Company”) announced that Mary Puncochar, who has served as the Company’s Head of Strategic Sales & Business Analytics since March 2024 and, prior to that, served as Chief Commercial Officer from May 2023 to March 2024, was terminated other than for cause from all employment and officer positions with the Company.”
biote Corp. reported first quarter ended March 31, 2024 results: revenue Revenue of $46.8 million, net income Net loss of $(5.8) million, EPS basic and diluted loss per share attributable to biote Corp. stockholders of $(0.06). Guidance reaffirmed.
“for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) • Revenue of $46.8 million, up 4.4% • Procedure revenue of $37.4 million, up 6.6% • Gross profit margin of 71.4%, an approximately 240-basis point increase • Net loss of $(5.8) million, representing net”
biote Corp. entered into Settlement Agreement with Dr. Gary S. Donovitz valued at approximately $76.9 million (effective 2024-04-23).
“On April 23, 2024, biote Corp., a Delaware corporation (the “Company”) entered into a Settlement Agreement (the “Settlement Agreement”) with respect to its previously disclosed litigation with one of the Company’s stockholders, Dr. Gary S. Donovitz (“Donovitz”) (the “Donovitz Litigation”).”
biote Corp. reported the full year ended December 31, 2023 results: revenue $185.4 million, net income $(2.8) million, EPS $0.13 per diluted share. Guidance reaffirmed.
“financial guidance • Adjusted EBITDA margin 1 of 29.7% Full Year 2023 Financial Highlights (All financial result comparisons made are against the prior year) • Revenue of $185.4 million, a 12.4% increase • Procedure revenue of $141.0 million, up 9.3% • Gross profit margin of 68.8%, an approximately 190-basis point increase • Net loss of $(2.8) million,”
biote Corp. reported the fourth quarter ended December 31, 2023 results: revenue $45.7 million, net income $12.1 million, EPS $0.18. Guidance reaffirmed.
“quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights (All financial result comparisons made are against the prior-year period) • Revenue of $45.7 million, a 2.7% increase and in line with pre-released financial guidance • Procedure revenue of $34.9 million, up 6.6% • Gross profit margin of 69.4%, a more than 400-basis point”
biote Corp. entered into Settlement Term Sheet with Dr. Gary S. Donovitz valued at approximately $76.9 million (effective 2024-02-13).
“On February 13, 2024, biote Corp., a Delaware corporation (the “Company”) entered into a binding settlement term sheet (the “Settlement Term Sheet”) with respect to its previously disclosed litigation with one of the Company’s stockholders, Dr. Gary S. Donovitz (“Donovitz”)”
biote Corp. updated its fiscal year ended December 31, 2024 guidance (initiated).
“the Company is providing initial 2024 financial guidance that management will discuss in more detail during the Company’s fiscal 2023 fourth quarter results conference call. Specifically, Biote projects fiscal 2024 revenue of greater than $200 million and Adjusted EBITDA of greater than $60 million.”
biote Corp. updated its the three months and year ended December 31, 2023 guidance (lowered).
“On January 17, 2024, biote Corp., a Delaware corporation (the “Company”) issued a press release to report preliminary financial results for the three months and year ended December 31, 2023.”
Samar Kamdar changed role as Chief Financial Officer at biote Corp..
“Samar Kamdar, the Company’s current Chief Financial Officer, will transition out of his role, effective immediately.”
Robert Peterson was appointed as Chief Financial Officer at biote Corp..
“On January 8, 2024, biote Corp. (the “Company”) appointed Robert Peterson as Chief Financial Officer (principal accounting and principal financial officer) of the Company, effective immediately.”
biote Corp. reported the third quarter ended September 30, 2023 results: revenue $45.6 million, net income $19.6 million, EPS $0.25 per basic share. Guidance reaffirmed.
“for the third quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights (All financial result comparisons made are against the prior year period) • Revenue of $45.6 million, an 8.5% increase • Gross profit margin of 68.9%, a 70-basis point increase • Net income of $19.6 million, representing net income margin of 43.1%, and basic earnings per share”
biote Corp. reported the second quarter ended June 30, 2023 results: revenue $49.3 million, net income $(13.1) million, EPS $(0.25). Guidance reaffirmed.
“for the second quarter ended June 30, 2023. Second Quarter 2023 Financial Highlights (All financial result comparisons made are against the prior year period) • Revenue of $49.3 million, a 19.1% increase • Gross profit margin of 67.9%, a 60-basis point increase • Net loss of $(13.1) million and GAAP loss per share of $(0.25), compared to a net loss of $(21.3)”
biote Corp. amended Warrant Amendment with Continental Stock Transfer & Trust Company (effective 2023-06-08).
“Accordingly, on June 8, 2023, the Company and the Warrant Agent entered into the Warrant Amendment, which permits the Company to require that each Warrant that is outstanding upon the closing of the Offer be converted into 0.207 shares of Common Stock”
biote Corp. shareholders rejected Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-05-17 meeting.
“Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the Annual Meeting was not approved. For Against Abstain Broker Non-Votes 19,843,341 21,464,530 0 0”
biote Corp. shareholders approved Election of Class I Directors at the 2023-05-17 meeting.
“Proposal 1: Election of Directors The individuals listed below were elected at the Annual Meeting to serve as Class I directors until the Company’s 2026 annual meeting of stockholders and until their successors are duly elected and qualified. Nominee For Withheld Broker Non-Votes Andrew R. Heyer 18,040,916 22,383,658 883,297 Dana Jacoby 18,163,539 22,261,035 883,297”
biote Corp. reported first quarter ended March 31, 2023 results: revenue $44.8 million, net income $(21.4) million, EPS $(0.39) per share. Guidance reaffirmed.
“hormone therapy, today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Highlights, year-over-year: • Revenue of $44.8 million, a 20.7% increase • Gross profit margin of 69.1%, a 220-basis point increase • Net loss of $(21.4) million and GAAP loss per share of $(0.39), primarily reflecting the impact”
biote Corp. reported 2023 results: revenue $190-200 million. Guidance initiated.
“Expect 2023 Revenue of $190-200 million and Adjusted EBITDA of $56-60 million”
biote Corp. reported the fiscal year ended December 31, 2022 results: revenue $165.0 million, net income $1.3 million, EPS $(0.12).
“Full Year 2022 Highlights, year over year: • Revenue of $165.0 million, an 18.3% increase. • Net income of $1.3 million and fully diluted GAAP loss per share of $(0.12).”
biote Corp. reported the fourth quarter ended December 31, 2022 results: revenue $44.5 million, net income $12.8 million, EPS $0.18.
“Fourth Quarter Highlights, year over year : • Revenue of $44.5 million, an 18.5% increase. • Net income of $12.8 million and fully diluted GAAP earnings per share of $0.18.”
biote Corp. reported that prior financial statements should not be relied upon.
“concluded that the Company’s previously issued unaudited interim condensed consolidated financial statements as of and for the three and six months ended June 30, 2022 and as of and for the three and nine months ended September 30, 2022 (the “Affected Financials”), each as previously filed with the SEC within the respective quarterly report on Form 10-Q, should no longer be relied upon”
biote Corp.: Amended and restated bylaws to update procedural mechanics for stockholder nominations and proposals, modify stockholder meeting procedures, and make other ministerial changes (effective 2023-02-21).
“On February 21, 2023, the Board approved and adopted the amended and restated bylaws (the “Amended and Restated Bylaws”), effective immediately.”
biote Corp. reported the third quarter ended September 30, 2022 results: revenue $42.0 million, net income $(6.3) million, EPS $(1.74). Guidance reaffirmed.
“set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Biote Reports Third Quarter Financial Results Strong Third Quarter Revenue of $42 million Driven by Growth in Procedures 2022 Revenue and Adjusted EBITDA Expected at Upper End of Guidance IRVING, TX – November 8, 2022 - Biote (NASDAQ: BTMD), a leading provider of”
Debra L. Morris was appointed as Director at biote Corp..
“On November 3, 2022, the Board of Directors (the “ Board ”) of biote Corp. (the “ Company ”) increased the size of the Board from six to seven directors and, following the recommendation of the Nominating and Corporate Governance Committee, appointed Debra L. Morris to serve as a member of the Board and as a member of the Board’s Audit Committee, effective immediately.”
Robbin Gibbins changed role as Chief Financial Officer at biote Corp..
“Robbin Gibbins, the Company’s current Chief Financial Officer, will transition out of his role, effective immediately.”
Samar Kamdar was appointed as Chief Financial Officer at biote Corp..
“On August 24, 2022, biote Corp. (the “Company”) announced the appointment of Samar Kamdar as Chief Financial Officer (principal accounting and principal financial officer) of the Company, effective immediately.”
Marc Beer was appointed as Executive Chairman at biote Corp..
“Marc Beer was appointed Executive Chairman of the Board.”
Marc Beer was appointed as Director at biote Corp..
“Teresa Weber, Andrew Heyer, Steven Heyer, Dana Jacoby, Mark Cone, M.D. and Marc Beer were appointed as directors of the Company”
Mark Cone was appointed as Director at biote Corp..
“Teresa Weber, Andrew Heyer, Steven Heyer, Dana Jacoby, Mark Cone, M.D. and Marc Beer were appointed as directors of the Company”
Dana Jacoby was appointed as Director at biote Corp..
“Teresa Weber, Andrew Heyer, Steven Heyer, Dana Jacoby, Mark Cone, M.D. and Marc Beer were appointed as directors of the Company”
Steven Heyer was appointed as Director at biote Corp..
“Teresa Weber, Andrew Heyer, Steven Heyer, Dana Jacoby, Mark Cone, M.D. and Marc Beer were appointed as directors of the Company”
Andrew Heyer was appointed as Director at biote Corp..
“Teresa Weber, Andrew Heyer, Steven Heyer, Dana Jacoby, Mark Cone, M.D. and Marc Beer were appointed as directors of the Company”
Teresa Weber was appointed as Director at biote Corp..
“Teresa Weber, Andrew Heyer, Steven Heyer, Dana Jacoby, Mark Cone, M.D. and Marc Beer were appointed as directors of the Company”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.